MedTrace Logo

Use of Stromal Vascular Fraction in Multiple Sclerosis

NCT03461419 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-12

No results posted yet for this study

Summary

Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via intravascular system of quality of life and alteration of documented Advanced Muscular Sclerosis (MS). It is believed that the heterogeneous cell population which includes multipotent stem/stromal cells plus non-multipotent cellular elements are capable of immune modulation/inflammatory modulation properties. Exam of disease progression and quality of life changes will be evaluated by sophisticated mathematical non-biased MRI analysis.

Conditions

Interventions

PROCEDURE

Microcannula Harvest Adipose Stroma

Use of Disposable, Closed Syringe Microcannula Harvest Autologous Adipose Stroma and Stem/Stromal Cells

DEVICE

Centricyte 1000

Centricyte 1000 closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature

PROCEDURE

Sterile Normal Saline IV Deployment of cSVF

Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery Including 150 micron in-line filtration

Sponsors & Collaborators

  • Global Alliance for Regenerative Medicine

    collaborator OTHER

  • Healeon Medical Inc

    lead INDUSTRY

Principal Investigators

  • Glenn C Terry, MD · GARM International

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2027-01-01
Completion
2028-12-15
FDA Device
Yes

Countries

  • United States
  • Honduras

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03461419 on ClinicalTrials.gov